Roche opens the week with half year results, shares in focus

Roche starts the week with a clear calendar item: the half year results presentation is set for 2026-07-23, and analysts still see a Buy consensus with an average target near CHF 359.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 14:55.

Roche (CH0012032048) opens the week with a defined calendar marker on SIX Swiss Exchange. Roche Investor Relations has scheduled its Half Year Results 2026 presentation for 2026-07-23, while MarketScreener still lists Roche as actively quoted in Zurich.

Half year date set

Roche’s investor page names the next major reporting step for 2026-07-23. The company also lists its IR contacts on the same update page, which confirms the presentation format and gives the event a dated frame.

The Swiss market backdrop is steady enough for a large-cap healthcare name to stay on the radar. MarketScreener’s Roche page shows a recent Swiss Exchange quote of CHF 325.80 on 2026-06-23, with 122,797 shares traded in the quoted line.

Consensus stays constructive

On consensus, Roche still carries a Buy rating on Investing.com, based on 18 analysts. The same page puts the average 12-month target at CHF 358.83, with a high estimate of CHF 428 and a low estimate of CHF 230.

That gap leaves the stock in a familiar analyst corridor. For retail readers, the useful point is not a forecast but the spread: the median view sits well above the latest quoted Swiss line.

The business behind the stock

Roche’s core business is biopharmaceuticals, with oncology, immunology and diagnostics at the center of the group’s model. The investor materials remain anchored in prescription medicines and diagnostic systems rather than consumer products.

Where Roche trades now

The Roche shares (CH0012032048) trade on 2026-06-23 at CHF 325.80 on the Swiss Exchange. The same as-of stamp appears in the fact box below.

Key data on Roche shares

• Company: Roche Holding AG
• ISIN: CH0012032048
• Ticker: ROG
• Trading venue: Swiss Exchange
• Price (as of 2026-06-23, 07:20): CHF 325.80
• Sector / industry: Pharmaceuticals, biotechnology and life sciences
• Next earnings date: 2026-07-23

Disclaimer: This article is for information only and does not constitute investment advice.